Who is sponsoring NCT04261972?

NCT04261972 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT04261972?

Interventions in NCT04261972: Next generation sequencing (NGS).

What condition does NCT04261972 study?

NCT04261972 studies Hereditary Cancer Syndrome.

Is NCT04261972 still recruiting?

NCT04261972 is currently active, enrolled. Last updated 14 January 2026.

Last reviewed 2026-01-14 · How we verify

NCT04261972: CHARM1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cell-free DNA in Hereditary And High-Risk Malignancies 1

Active, enrolled Last updated 14 January 2026

What this trial tests

trial testing Next generation sequencing (NGS) in Hereditary Cancer Syndrome in 1,416 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 July 2018

Primary endpoint
31 December 2024

31 December 2026

Quick facts

Lead sponsor	University Health Network, Toronto
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	1,416
Start date	1 July 2018
Primary completion	31 December 2024
Estimated completion	31 December 2026
Sites	7 locations across Canada

Drugs / interventions tested

Next generation sequencing (NGS)

Conditions studied

Hereditary Cancer Syndrome — all drugs for Hereditary Cancer Syndrome →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Hereditary Cancer Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS). If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. The study will also use questionnaires and interviews to understand how patients feel about incorporating these tests into routine medical care, and the perceptions of the medical value of test results.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Management of High-Grade Serous Ovarian Carcinoma.
Punzón-Jiménez P, Lago V, Domingo S, Simón C, et al · · 2022 · cited 28× · PMID 36430255 · DOI 10.3390/ijms232213777
"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management.
Shickh S, Oldfield LE, Clausen M, Mighton C, et al · · 2022 · cited 7× · PMID 35385106 · DOI 10.1093/oncolo/oyac039
Liquid biopsy-based early tumor and minimal residual disease detection<b>: New perspectives for cancer predisposition syndromes</b>.
Bohaumilitzky L, Gebert J, Doeberitz MVK, Kloor M, et al · · 2023 · cited 3× · PMID 38835740 · DOI 10.1515/medgen-2023-2049
Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.
Garcia-Pelaez J, Yáñez Y, Aupí M, Lázaro M, et al · · 2026 · PMID 42194957 · DOI 10.3390/genes17050500

Verify or expand the search:

Other trials of Next generation sequencing (NGS)

Trials testing the same drug.

NCT03597958 — Genetic Causes of Hypercholesterolaemia in the Emirati Population · unknown
NCT03589092 — Genetic Causes of Gestational Diabetes in the Emirati Population · unknown
NCT03607604 — Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE · unknown

Other recruiting trials for Hereditary Cancer Syndrome

Currently open trials in the same condition.

NCT07195071 — Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening · NA · recruiting
NCT06708429 — Lynch Syndrome X-Talk of Enteral Mucosa With Immune System · recruiting
NCT04541654 — Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04261972 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 14 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04261972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing